» Articles » PMID: 27105855

Proteasomes Regulate Hepatitis B Virus Replication by Degradation of Viral Core-related Proteins in a Two-step Manner

Overview
Journal Virus Genes
Date 2016 Apr 24
PMID 27105855
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The cellular proteasomes presumably inhibit the replication of hepatitis B virus (HBV) due to degradation of the viral core protein (HBcAg). Common proteasome inhibitors, however, either enhance or inhibit HBV replication. In this study, the exact degradation process of HBcAg and its influences on HBV replication were further studied using bioinformatic analysis, protease digestion assays of recombinant HBcAg, and proteasome inhibitor treatments of HBV-producing cell line HepG2.2.15. Besides HBcAg and hepatitis B e antigen precursor, common hepatitis B core-related antigens (HBcrAgs), the small and the large degradation intermediates of these HBcrAgs (HBcrDIs), were regularly found in cytosol of HepG2.2.15 cells. Further, the results of investigation reveal that the degradation process of cytosolic HBcrAgs in proteasomes consists of two steps: the limited proteolysis into HBcrDIs by the trypsin-like (TL) activity and the complete degradation of HBcrDIs by the chymotrypsin-like (chTL) activity. Concordantly, HBcrAgs and the large HBcrDI or HBcrDIs (including the small HBcrDI) were accumulated when the TL or chTL activity was inhibited, which generally correlated with enhancement and inhibition of HBV replication, respectively. The small HBcrDI inhibited HBV replication by assembling into the nucleocapsids and preventing the victim particles from being mature enough for envelopment. The two-step degradation manner may highlight some new anti-HBV strategies.

Citing Articles

The ubiquitin-proteasome system is required for African swine fever replication.

Barrado-Gil L, Galindo I, Martinez-Alonso D, Viedma S, Alonso C PLoS One. 2017; 12(12):e0189741.

PMID: 29244872 PMC: 5731689. DOI: 10.1371/journal.pone.0189741.


Glucose-regulated protein 78 demonstrates antiviral effects but is more suitable for hepatocellular carcinoma prevention in hepatitis B.

Zheng N, Zheng Z, Xu H, Huang M, Peng X Virol J. 2017; 14(1):77.

PMID: 28407787 PMC: 5390389. DOI: 10.1186/s12985-017-0747-z.

References
1.
Liaw Y . Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009; 29 Suppl 1:100-7. DOI: 10.1111/j.1478-3231.2008.01941.x. View

2.
Jung J, Kim H, Kim T, Shin B, Park G, Park S . C-terminal substitution of HBV core proteins with those from DHBV reveals that arginine-rich 167RRRSQSPRR175 domain is critical for HBV replication. PLoS One. 2012; 7(7):e41087. PMC: 3401125. DOI: 10.1371/journal.pone.0041087. View

3.
Biermer M, Puro R, Schneider R . Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol. 2003; 77(7):4033-42. PMC: 150632. DOI: 10.1128/jvi.77.7.4033-4042.2003. View

4.
Zhang Z, Sun E, Ou J, Liang T . Inhibition of cellular proteasome activities mediates HBX-independent hepatitis B virus replication in vivo. J Virol. 2010; 84(18):9326-31. PMC: 2937595. DOI: 10.1128/JVI.00579-10. View

5.
Sohn S, Kim S, Kim J, Ahn B . Negative regulation of hepatitis B virus replication by cellular Hsp40/DnaJ proteins through destabilization of viral core and X proteins. J Gen Virol. 2006; 87(Pt 7):1883-1891. DOI: 10.1099/vir.0.81684-0. View